<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307463</url>
  </required_header>
  <id_info>
    <org_study_id>Ege1336</org_study_id>
    <nct_id>NCT00307463</nct_id>
  </id_info>
  <brief_title>Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation</brief_title>
  <official_title>Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation: a Randomised, Prospective and Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ege University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ege University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims mainly to investigate the effects of two approaches to control blood pressure
      in hypertensive hemodialysis patients; using antihypertensive drugs versus strict volume
      control (by strict dietary salt restriction and persistent ultrafiltration) without using
      antihypertensive drugs on cardiac structure and inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomised, controlled and prospective study aims mainly to investigate the effects of
      two approaches to control blood pressure in hypertensive hemodialysis patients; using
      antihypertensive drugs versus persistent strict volume control without using antihypertensive
      drugs on cardiac structure (mainly left ventricular hypertrophy)and inflammation.

      We hypothesize that better blood pressure control and regression of left ventricular mass may
      be reached by a policy of strict volume control consisting of strict dietary salt restriction
      and persistent ultrafiltration.

      258 Hypertensive hemodialysis patients (BP&gt;130/80 mmHg and/or being on antihypertensive
      medication) will be randomized to two arms:

      Group 1: Antihypertensive medicine will be stopped and strict volume control policy will be
      applied.

      Group 2: Antihypertensive medicine will be continued. Target BP will be 130/80 mmHg in both
      groups.

      The patients will be evaluated at 12 months for primary outcomes. Primary end-points are
      significant changes in left ventricular hypertrophy and left ventricular mass and significant
      change in left ventricular end-diastolic volume.

      Secondary end-points are changes in post-dialysis weight, changes in hematocrit, albumin, BNP
      and hsCRP levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>regression of left ventricular hypertrophy</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>regression of left ventricular mass</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in left ventricular end-diastolic volume</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in post-dialysis weight, changes in hematocrit, albumin, changes in BNP and hsCRP levels</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>strict volume control policy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>strict volume control policy: Antihypertensive medicine will be stopped and strict volume control policy will be applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antihypertensive drugs administration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>antihypertensive drugs administration: Antihypertensive medicine will be continued. Target BP will be 130/80 mmHg in both groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>strict volume control policy</intervention_name>
    <description>strict volume control by UF and dietary salt restriction</description>
    <arm_group_label>strict volume control policy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antihypertensive drugs administration</intervention_name>
    <description>continue antihypertensive medications</description>
    <arm_group_label>antihypertensive drugs administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged between 18-70 years old

          -  on maintenance bicarbonate hemodialysis scheduled thrice weekly, at least 12
             hours/week

          -  willingness to participate in the study with a written informed consent.

        Exclusion Criteria:

          -  to be scheduled for living donor renal transplantation

          -  to have serious life-limiting co-morbid situations; namely active malignancy, active
             infection, end-stage cardiac, pulmonary, or hepatic disease; pregnancy or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ercan Ok, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Ege University School of Medicine Nephrology Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ege University School of Medicine Division of Nephrology</name>
      <address>
        <city>Bornova</city>
        <state>Izmir</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adana Numune Research and Education Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2006</study_first_posted>
  <last_update_submitted>September 6, 2013</last_update_submitted>
  <last_update_submitted_qc>September 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ege University</investigator_affiliation>
    <investigator_full_name>Ercan OK</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>end-stage renal disease</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>volume control</keyword>
  <keyword>ultrafiltration</keyword>
  <keyword>inflammation</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>left ventricular hypertrophy</keyword>
  <keyword>dietary salt restriction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

